Monograph
B01AA07 - Acenocoumarol |
Propably not porphyrinogenic |
PNP |
Rationale
Acenocoumarol is metabolized by CYP 2C9, 1A2 and 2C19, but induction or inhibition of the CYP enzymes are not observed or suspected.
Chemical description
Acenocoumarol is a coumarin derivate.
Therapeutic characteristics
Acenocoumarol is a coumarin derivative and functions as vitamin K antagonist. It is used in the treatment and prevention of thromboembolic diseases.
It is administered orally and the elimination half-life from the plasma is from 8 to 11 hours.
Metabolism and pharmacokinetics
Acenocoumarol is metabolized mainly by CYP 2C9, but CYP1A2 and CYP 2C19 are also involved (Thijssen 2000, Ufer 2005).
No CYP relevant drug-drug interaction with acenocoumarol as a perpetrator has been reported in the literature (Lexi-Interact, Micromedex, SPC).
IPNet drug reports
Uneventful use reported in 5 patients with acute porphyria.
References
| # | Citation details | PMID |
|---|---|---|
| * | Scientific articles | |
| 1. | Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.
Thijssen HH, Flinois JP et al. Drug Metab Dispos. 2000 Nov;28(11):1284-90. |
11038154 |
| 2. | Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
Ufer M. Clin Pharmacokinet. 2005;44(12):1227-46. |
16372822 |
| * | Drug interaction databases | |
| 3. | Lexi-Interact, via UpToDate.
|
|
| 4. | Micromedex® 2.0 (online). Drug Interactions). (24.05.2017).
|
|
| * | Summary of Product Characteristics | |
| 5. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC).Sinthrome.
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Norway
Poland
Luxembourg
Serbia© NAPOS 2024